Masera and colleagues recently published case reports of lens opacities in three patients with b-thalassemia major that were suggested to be associated with exposure to deferasirox (ICL670, Exjade); the opacities developed 7, 16 and 26 months after initiating deferasirox therapy. These three patients are from a total of 12 being followed by the authors at their institution. This reported incide...

Isoflavones are commonly consumed in many Asian countries and have potentially positive effects on human being. Only a few and rather controversial data on their interactions with copper and iron are available to date. 13 structurally related isoflavones were tested in the competitive manner for their Cu/Fe-chelating/reducing properties. Notwithstanding the 5-hydroxy-4-keto chelation site was a...

OBJECTIVE This prospective pilot study aimed at evaluating the effects of therapy with antioxidant compounds (Cellfood, and other antioxidants) on patients affected by neurodegenerative diseases (ND), who displayed toxic metal burden and were subjected to chelation treatment with the chelating agent calcium disodium ethylenediaminetetraacetic acid (CaNa2EDTA or EDTA). METHODS Two groups of su...

Iron chelation therapy is often used to treat iron overload in patients requiring transfusion of red blood cells (RBC). A 76-year-old man with MDS type refractory cytopenia with multilineage dysplasia, intermediate-1 IPSS risk, was referred when he became transfusion dependent. He declined infusional chelation but subsequently accepted oral therapy. Following the initiation of chelation, RBC tr...

TREATMENT OF LEAD TOXICITY with chelation was first reported with EDTA in the early 1950s. Apparent success in reducing metastatic calcium deposits led Clarke et al in 1956 to treat angina patients with EDTA, and others to use chelation for various forms of atherosclerotic disease. Chelation therapy evolved to constitute infusions of vitamins and disodium EDTA, a drug that binds divalent and so...

PURPOSE To determine whether low-normal body lead burden (BLB) accelerates progressive renal insufficiency in nondiabetic patients with chronic kidney diseases (CKD). METHODS One hundred eight CKD patients (serum creatinine between 1.5 and 2.9 mg/dL) with low-normal BLB (<80 microg) and no lead exposure history were observed for 24 months. Following the observation, 32 patients with low-norma...

 abstract the present study aimed to determine the prevalence of hypothyroidism, hypoparathyroidism and the frequency of regular chelation therapy in patients with thalassemia major in iran. searching process was performed by two independent  researchers using valid keywords in the national and international database, including: magiran, iranmedex, sid, medlib, scopus, pubmed, science direct, ...

Background: Thalassemia is a series of hemoglobinopathies in which the production of perfect hemoglobin is completely or partially suppressed. Using injectable iron chelators have been dominating treatment for the iron overload caused by recurrent blood transfusions in thalassemic patients, however, a new oral iron chelating drug (Exjade) have been recently introduced and might be cost effec...